ÌÒÉ«ÊÓƵ

Commonly used industrial dyes hold the key to advancing the new science of 'spintronics', say researchers working on a new a £2.5 million study.

Spintronics holds out the possibility of a range of future applications, such as quantum computing, which aims to deliver secure, low-power computers capable of processing much larger quantities of data than is currently possible. Scientists believe that sensitive new biosensors able to analyse blood or urine samples rapidly and accurately could also be developed as a result of this work.

The new Basic Technology grant awarded by the Engineering and Physical Sciences Research Council will support research into the magnetic properties of metal atoms found in industrial dyes such as Metal Phthalocyanine (MPc), a blue dye used in clothing. The team from the London Centre for Nanotechnology - a joint venture between Imperial College London and University College London - and the University of ÌÒÉ«ÊÓƵ believes that finding ways to control and exploit these molecules will allow spintronics to be applied in new ways.

The Macro Group UK met at ÌÒÉ«ÊÓƵ Chemistry for their annual Frontiers in Science Meeting in Combination with the Young Persons Research Meeting.

148 delegates from all over the UK were attending the conference which made it the one of the largest and most successful meetings the Macro Group UK ever had of this type.

Dave Haddleton, Chair of the Macro Group UK said: "To have approximately 130 polymer chemistry students from all over the UK having such a great time scientifically and socially is fantastic for UK polymer chemistry and also for ÌÒÉ«ÊÓƵ Chemistry and the University"

Chair organiser of the conference was assistant professor Andrew Dove from ÌÒÉ«ÊÓƵ Chemistry.

Patrick Colver, a final year PhD student in Stefan Bon's group was one of the winners of the best poster prize.

Photos of the meeting can be found

Iron regulation

New Role For Transferrin

Blood protein forms fibers, releases rust

Transferrin, the blood protein responsible for transporting iron throughout the body, can assemble into fibers that release bits of rust (Angew. Chem. Int. Ed., DOI: 10.1002/anie.200705723). These unexpected findings from in vitro studies may help researchers decipher iron's role in various neurodegenerative diseases.

Howard Lightfoot and Arindam Mukherjee

Transferrin's Fe³⁺-binding site grips the metal (small orange ball) with a carbonate anion, two tyrosinates, an aspartate, and a histidine.

Diseases such as Parkinson's, Alzheimer's, and Huntington's have been associated with the defective regulation of iron in the brain. "If transferrin plays a role in accumulation of iron in brain tissue, then understanding the mechanism of this process will allow the design of drugs that could disrupt transferrin aggregation," says , a chemistry professor at the University of ÌÒÉ«ÊÓƵ, in England. Sadler carried out the work in collaboration with chemistry professor of the Indian Institute of Technology, Kanpur, and colleagues.

Their findings have intrigued other researchers. "Transferrin has never been shown to form fibrils, let alone ones with pockets of mineralized iron," says N. Dennis Chasteen, a chemistry professor at the University of New Hampshire. "Until this paper, human serum transferrin had been universally thought of simply as a transport protein for iron and other metals in blood circulation."

Transferrin is best known for transporting two Fe³⁺ ions. Each ion is tightly bound to four amino acid side chains that form a compartment and a carbonate anion that acts as a synergistic keystone.

Sadler and his colleagues deposited dehydrated transferrin on various surfaces under conditions that mimic living systems. They used microscopy techniques to show that the protein assembles into fibers and forms metal nanocrystals. Diffraction patterns indicate similarities in composition between the crystals and an iron oxide mineral called lepidocrocite. The researchers plan further experiments to see whether transferrin fibers form and iron minerals accumulate in vivo.

Researchers from the Universities of ÌÒÉ«ÊÓƵ, Edinburgh, Dundee and the Czech Republic’s Institute of Biophysics have discovered a new light-activated platinum-based compound that is up to 80 times more powerful than other platinum-based anti-cancer drugs and which can use "light activation" to kill cancer cells in much more targeted way than similar treatments.

The platinum-based compound known as "trans, trans, trans- [Pt(N3)2(OH)2(NH3)(py)]", or a light activated PtIV complex, is highly stable and non-toxic if left in the dark but if light falls upon it becomes much less stable and highly toxic to cancer cells. In fact it is between 13 and 80 times more toxic (depending on how and on which cells it is used) to cancer cells than the current platinum based anti-cancer drug Cisplatin. Moreover it kills the cells by a different mechanism of action, so it can also kill cisplatin-resistant cells.

Professor Peter Sadler, Chairman of the Chemistry Department of the University of ÌÒÉ«ÊÓƵ, who led the research project said:

"Light activation provides its massive toxic power and also allows treatment to be targeted much more accurately against cancer cells."

The compound could be used in particular to treat surface cancers. Patients could be treated in a darkened environment with light directed specifically at cancer cells containing the compound activating the compound’s toxicity and killing those cells. Normal cells exposed to the compound would be protected by keeping the patient in darkness until the compound has passed through and out of the patient.

The new light activated PtIV complex is also more efficient in its toxic action on cancer cells in that, unlike other compounds currently used in photodynamic therapy, it does not require the presence of significant amounts of oxygen within a cancer cell to become toxic. Cancer cells tend to have less oxygen present than normal cells.

Although this work is in its early stages, the researches are hopeful that, in a few years time, the new platinum compound could be used in a new type of photoactivated chemotherapy for cancer.

Peter Dunn, Press and Media Relations Manager,
University of ÌÒÉ«ÊÓƵ, 024 76 523708
mobile 07767 655860 p.j.dunn@warwick.ac.uk

PR112 PJD 21st December 2007

The University Of ÌÒÉ«ÊÓƵ has just been awarded £4 Million under the government’s Science and Innovation scheme to develop a new Centre in Analytical Science.  The Centre will develop new analytical approaches and use the very latest technology and techniques in scientific measurement and data analysis. The Centre will bring together scientists from broadly across the University to pool their expertise being led from Chemistry, but including computer scientists, physicists, life scientists, medical researchers, statisticians, and engineers.

For more information please contact:           

Professor Mark Smith, University of ÌÒÉ«ÊÓƵ
Tel: 024 76 522380

Peter Dunn, Press and Media Relations Manager,
University of ÌÒÉ«ÊÓƵ,  024 76 523708 or 007767 655860  

Giovanni Costantini  transfers to ÌÒÉ«ÊÓƵ Chemistry being the former group leader of the in the headed by Prof. Klaus Kern at the in Stuttgart. He will take up his position full-time from January 2008. 

Recent work under ÌÒÉ«ÊÓƵ Chemistry affiliation already includes: 

Wang, Y.; Lingenfelder, M.; Classen, T.; Costantini, G.; Kern, K.
J. Am. Chem. Soc.; (Communication); 2007; ASAP Article;  DOI:
10.1021/ja075118v


Tomba, G.; Lingenfelder, M.; Costantini, G.; Kern, K.; Klappenberger,
F.; Barth, J. V.; Ciacchi, L. C.; De Vita, A.
J. Phys. Chem. A.; (Article); 2007; 111(49); 12740-12748. 


Classen, T.; Lingenfelder, M.; Wang, Y.; Chopra, R.; Virojanadara, C.;
Starke, U.; Costantini, G.; Fratesi, G.; Fabris, S.; de Gironcoli, S.;
Baroni, S.; Haq, S.; Raval, R.; Kern, K.
J. Phys. Chem. A.; (Article); 2007; 111(49); 12589-12603. 

A review on by the Peter Sadler  team was the most downloaded paper in Chem.Soc.Rev. in November 2007.

In this critical review we discuss recent advances in understanding the modes of interaction of metal ions with membrane proteins, including channels, pumps, transporters, ATP-binding cassette proteins, G-protein coupled receptors, kinases and respiratory enzymes. Such knowledge provides a basis for elucidating the mechanism of action of some classes of metallodrugs, and a stimulus for the further exploration of the coordination chemistry of metal ions in membranes. Such research offers promise for the discovery of new drugs with unusual modes of action. The article will be of interest to bioinorganic chemists, chemical biologists, biochemists, pharmacologists and medicinal chemists. (247 references)

by Stefan Bon's research team is in the top 20 summer 2007 downloads in Langmuir.

Abstract:

Solid-stabilized, or Pickering, miniemulsion polymerizations using Laponite clay discs as stabilizer are investigated. Free radical polymerizations are carried out using a variety of hydrophobic monomers (i.e., styrene, lauryl (meth)acrylate, butyl (meth)acrylate, octyl acrylate, and 2-ethyl hexyl acrylate). Armored latexes, of which the surfaces of the particles are covered with clay discs, are obtained, as confirmed by scanning electron microscopy (FE-SEM) and atomic force microscopy (AFM). Overall polymerization kinetics of the Pickering miniemulsion polymerizations of styrene were investigated via gravimetry. Comparison with the bulk polymerization analogue clearly shows compartmentalization. Moreover, retardation effects up to intermediate monomer conversions are observed; they are more prominent for the smaller particles and are ascribed to the Laponite clay. A model is presented that allows for the prediction of the average particle size of the latexes produced as a function of the amounts of monomer and Pickering stabilizers used. It shows that under specific generic conditions the number of clay discs used correlates in a linear fashion with the total surface area of the latex particles. This is a direct result of the reversibility of the Laponite clay disc adhesion process under the emulsification conditions (i.e., sonication) used.

James D. Hoeschele, Abraha Habtemariam, Jeanette Muir and Peter J. Sadler, Dalton Trans., 2007
DOI:

The organometallic half-sandwich Ru^II arene anticancer complex [(⁶-fluorene)Ru(en)Cl]PF₆ (1) has been synthesized in high yield and purity on a micromole scale with incorporation of the -emitting radioisotope ¹⁰⁶Ru (half-life = 1.01 y) using a refined procedure involving conversion of RuCl₃ into [(⁶-fluorene)RuCl₂]₂, and then [(⁶-fluorene)Ru(CH₃CN)₂Cl]PF₆ as intermediates. Distribution studies 0.25 h post i.v. injection of ¹⁰⁶Ru-1 at a dose of 25 mg 1 kg^–1 show that ¹⁰⁶Ru is well distributed throughout the tissues of a rat. This appears to be the first report of the radiolabelling of a potential ruthenium antitumour agent for distribution/biological studies.

by Tim Jones' team in top 10 downloads in J.Mater.Chem. (September 2007)